On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Expanding Commercialization of Wearable Pain-Management Device

Company: Endonovo Therapeutics Inc. (ENDV)
Category: Stock Spotlights

Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical® therapeutic devices, has completed clinical trials and is currently expanding commercialization of its SofPulse® device that delivers pulsed electromagnetic frequencies for pain management. An article discussing the company reads, “In August, Endonovo announced its Q2 financial results, showing growth in both revenue and gross profits. However, since the economic potential for a safe, nonaddictive alternative to opioids is significant, the company’s continued progress as it reaches developmental and test milestones is clearly the key focus. Over the second quarter of 2019, the company expanded SofPulse® commercialization and announced the first commercial sales of the device for post-operative pain and edema. ‘The opioid epidemic is a major issue in society today, making SofPulse® a significant alternative to postoperative pain management. We believe we have laid the foundation for rapid growth and expansion,’ Endonovo CEO Alan Collier said in a company news release (http://nnw.fm/2gzUv).”

To view the full article, visit http://nnw.fm/oF15s

About Endonovo Therapeutics

Endonovo Therapeutics is a commercial-stage developer of noninvasive, wearable Electroceuticals® therapeutic devices. The company’s current portfolio of commercial and clinical-stage wearable Electroceuticals® therapeutic devices addresses wound healing, pain, postsurgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (“CNS”) disorders including traumatic brain injury (“TBI”), acute concussions, postconcussion syndrome and multiple sclerosis. The company’s noninvasive Electroceutical® therapeutic device, SofPulse®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA cleared and CE marked for the palliative treatment of soft-tissue injuries and postoperative pain and edema and has CMS national coverage for the treatment of chronic wounds. The company’s current portfolio of preclinical-stage Electroceuticals® therapeutic devices addresses chronic kidney disease, liver-disease nonalcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The company’s noninvasive, wearable Electroceuticals® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for healing to occur. For more information, visit the company’s website at www.Endonovo.com.

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://nnw.fm/ENDV

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217